Mayo Clinic pal Cardio3 reports 'promising' results
Here's an interesting update on the progress of a Belgium biotech firm using Mayo Clinic technology to try to find the Holy Grail of cardiac treatments - repair a damaged heart with a patient's own stem cells.
Here's the official word on the current relationship:
Mayo Clinic owns an equity position in the company. Mayo Clinic, and the inventors of the technology, Drs. Andre Terzic and Atta Behfar, have a financial interest. While no royalties have accrued to date, Mayo Clinic has rights to receive future royalties which will be shared with Drs. Terzic and Behfar in accordance with the Mayo Clinic Royalty sharing policy.
Anyway, Cardio3 rolled out results today at a conference in New Orleans that they say s
how improvement in heart failure patients after six months of treatment.
Here's some from that release:
Cardio3 BioSciences presented detailed data from the Phase II clinical trial of C3BS-CQR-1 (C-Cure(R)), its novel stem cell therapy for ischemic cardiomyopathy, at the 60th annual American College of Cardiology in New Orleans, USA.
The data were presented by Dr. Jozef Bartunek, Associate Director of the Cardiovascular Center in Aalst, Belgium and Co-Principal Investigator of the C3BS-CQR-1 (C-Cure) trial. The trial demonstrates that heart failure patients improved heart function and exercise capacity at 6 months following treatment
of C-Cure, an innovative and proprietary stem cell therapy based on the Company's "Cardiopoiesis" technology.
The Cardiopoiesis platform is based on fundamental research conducted at Mayo Clinic and is designed to drive the differentiation of adult bone marrow-derived stem cells into cardiac progenitor cells which have the potential to promote heart regeneration when re-injected into the heart of patients suffering from ischemic heart failure.
Dr. Christian Homsy, CEO of Cardio3 BioSciences, said: "Heart failure affects 117 million people and cannot be cured today as current therapies only reduce the severity of disease symptoms. Regenerative therapies, such as C-Cure, may offer new hope to patients who currently have limited choices and potentially avoid the need for heart transplantation.
The positive outcome of this study reiterates our belief that C-Cure can make a real difference to patients suffering from heart failure. Indeed, we are currently planning the next stages of C-Cure development and are committed to taking the steps needed to successfully bring this new and important treatment to patients. With C-Cure, we aim to become the first company with an approved regenerative product for ischemic heart failure."